Enoblituzumab
Monoclonal antibody
- none
- 1353485-38-7
- none
- M6030H73N9
- D11752
Enoblituzumab is a monoclonal antibody designed for the treatment of cancer.[1] Formerly known as MGA271, the drug is a humanized IgG1κ monoclonal antibody recognizing human B7-H3, a member of the B7 family of immune regulators.
This drug was developed by MacroGenics, Inc.
References
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Enoblituzumab, American Medical Association.
- v
- t
- e